The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG) Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV).
Available for licensing from the Laboratory of Cancer Biology and Genetics of the National Cancer Institute (NCI) is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several cancers, including, but not limited to: multiple myeloma, melanoma, and lung and breast cancers.
Meningitis A is a devastating disease afflicting 26 countries in Africa’s meningitis belt across sub-Saharan Africa. Thousands of people would die or be disabled each year, such as the 1996-97 epidemic when 25,000 were killed and a quarter million afflicted. The disease primarily afflicts young adults and children, leaving many wage earners with permanent brain damage. The Meningitis Vaccine Program (MVP) was formed by the health non-profit PATH, the Bill & Melinda Gates Foundation, and the World Health Organization to combat this epidemic.
Meningococcal meningitis, a bacterial infection of the brain that sweeps across sub-Saharan Africa in an area called the “meningitis belt,” is now losing its power to inflict illness and death. Scientists and technology transfer officers from the U.S.